

Name(s)

- **Generic:** esketamine (es KET a meen) | **Brand:** Spravato Nasal Spray

Therapeutic Category

- Antidepressant | Non-Selective, Non-Competitive N-methyl-D-aspartate (NMDA) Receptor Antagonist

Indication(s)

1. **Treatment-resistant depression (TRD):** Approved for use in adults taking an oral antidepressant.
2. **Depressive symptoms in Adults w/ Major Depressive Disorder (MDD) w/ Acute Suicidal Ideation/Behavior:** Approved for use in adults taking an oral antidepressant.

Dosage Form & Strength

- **Nasal Spray:** (Spravato "Brand Only") 56 mg, 84 mg

Dosing by Indication

- **Dosing for Treatment-resistant depression (TRD) in Adults**
 - Administered in conjunction with an oral antidepressant
 - **Induction Phase for weeks 1-4:** Administered intranasally bid. Starting dose is 56 mg on day one and subsequent doses are 56 mg or 84 mg
 - **Maintenance Phase for weeks 5-8:** Administer 56 mg or 84 mg intranasally once weekly. **Week 9 and after** is 56 mg or 84 mg intranasally administered every 1-2 weeks
- **Dosing for Depressive symptoms in Adults w/ Major Depressive Disorder (MDD) w/ Acute Suicidal Ideation/Behavior in Adults**
 - Administered in conjunction with an oral antidepressant
 - Recommended dosage is 84 mg twice per week for 4 weeks. May reduce 56 mg twice per week based on tolerability. After 4 weeks the therapeutic benefit of continued usage should be evaluated.

Mechanism of Action & Pharmacology

- **MOA:** Esketamine is the S-enantiomer of racemic ketamine. It is a non-selective and non-competitive antagonist of the NMDA receptor. The exact antidepressant effect is unknown.
- **Pharmacodynamics** in regards to cardiac electrophysiology has shown a large increase in heart rate but lacks relevancy to Qtc prolongation when used in therapeutic doses
- **Absorption:** 48% bioavailable | **Protein Binding:** 43-45% | **Elimination:** Biphasic w/ a rapid decline in the first 2-4 hours | **Half-Life:** 7-12 hours | **Metabolism:** CYP2B6, CYP3A4, and to a lesser extent CYP2C9 and CYP2C19 | **Excretion:** <1% is unchanged in urine

Special Populations & Considerations

- **Limitation of Use:** Efficacy in reducing or preventing suicide or suicidal behavior has not been proven. The use of Spravato as an anesthetic agent has not been approved.
- Not recommended for **pediatric** use



- Do not administer if patient has **blood vessel disease, abnormal connection between veins and arteries, history of bleeding in brain, or hypersensitivity reactions.**
- Not recommended in **pregnancy**

Side Effects

- **48-61%:** Sedation
- **Others:** Dissociation, increase in blood pressure, cognitive impairment, impaired ability to drive and operate machinery, ulcerative or interstitial cystitis, embryo-fetal toxicity

Risk Evaluation and Mitigation Strategy (REMS): Sedation, Dissociation, Abuse/Misuse – Only available through REMS program and can only be administered at healthcare settings certified in the Spravato REMS program.

Drug Interactions

- **Antidepressants** medicines may increase suicidal thoughts/actions
- CNS depressants (**benzodiazepines, opioids, alcohol**) may increase sedation
- Stimulants (**amphetamines, methylphenidate, modafinil, armodafinil**) may increase sedation
- **MAOIs** may increase blood pressure

Monitoring Parameters

- Blood pressure:
 - If baseline BP is elevated (>140 mmHg systolic, >90 mmHg diastolic) consider risk
 - Reassess blood pressure at approximately 40 minutes
- Changes in mood, behavior, thoughts, and feelings.
- Abuse and Misuse

Patient Counseling Information

- Spravato nasal spray is administered yourself under a healthcare providers' supervision
- Treatment schedules are to be followed exactly as specified by healthcare providers
- Do not drive or operate machinery after taking Spravato
- If a nasal corticosteroid or nasal decongestant is being used by the patient, administer Spravato at least 1 hour before the other medications

Reference(s)

- <https://www.spravato.com/>
- <https://www.janssenlabels.com/package-insert/product-patient-information/SPRAVATO-medication-guide.pdf>
- <https://www.drugs.com/pro/spravato.html>
- <https://www.rxlist.com/spravato-drug.htm>




PREPARE FOR SUCCESS!

Comprehensive (NAPLEX)





Calculations (NAPLEX)



Pharmacy Law (MPJE)



Supplemental



DISCLAIMERS

This page contains affiliate links. Buying something through a link will provide a small monetary commission to Drug Cards Daily at no cost to you! This is done to keep Drug Cards Daily going and to provide as much free content to people like you! Thank you so very much for your support! Also, images are property of their respective parties and can be removed by contacting Drug Cards Daily.

DRUG CARDS DAILY

Monday at 7 am EST
(6 am CST, 4 am PST)

HEY NEW GRAD!

So you landed that perfect job offer or got the perfect match for your PGY1 and now the **ONLY** thing standing in your way is passing the NAPLEX and MPJE.

Here are some NAPLEX & MPJE prep recommendations to help you do everything you can to **pass the first time!**

HEY STUDENT!

When I was P1 one of the best pieces of advice I got from those before me was to use a NAPLEX Prep book while learning each topic.

This helps focus your learning and the repetition helps to retain info and indirectly prepare you for the NAPLEX



@drugcardsdaily